Clinical trials: Spinal Cord Diseases
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
The study will generate data on safety, tolerability and pharmacokinetics after multiple daily doses of CK-2017357 in patients with ALS.
- Trial name
- NCT01378676
- Testing
- CK-2017357 (Part A), Riluzole 50 MG (Part B), CK-2017357 (Part B)
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- Cytokinetics
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Tazbentetol in ALS Participants
The objectives of this study are to examine the effects of tazbentetol on clinical measures of ALS, patient reported outcomes (PROs), long-term safety and tolerability.
- Trial name
- NCT07325591
- Testing
- Tazbentetol
- Volunteers
- 430 people
- Sponsor
- Spinogenix
Radiculopathy, Myelopathy
PCM Cervical Disc System
The PCM Cervical Disc was studied in a prospective, multicenter, randomized FDA-approved investigational device exemption (IDE) clinical trial conducted in the United States to evaluate longitudinal outcomes over 2 years…
- Trial name
- NCT00578812
- Testing
- Anterior Cervical Discectomy and Fusion (ACDF), PCM Cervical Disc
- Where
- 23 sites in United States
- Volunteers
- 494 people
- Sponsor
- NuVasive
Spinal Muscular Atrophy
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 1 (SMA 1) patients.
- Trial name
- NCT05824169
- Testing
- GC101
- Where
- 4 sites in China
- Volunteers
- 18 people
- Sponsor
- GeneCradle Inc
Diphtheria, Tetanus
Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants
The purpose of this trial is to clinically confirm that the manufacturing process of the final bulk products of the investigational DTaP-IPV-HB-PRP~T vaccine is consistent.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00404651
- Testing
- DTaP-IPV-HB-PRP~T vaccine, DTaP-HBV-IPV vaccine
- Where
- 6 sites in Mexico
- Volunteers
- 1,189 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
ALS (Amyotrophic Lateral Sclerosis), SMA - Spinal Muscular Atrophy
Register for Medical Data, Functional Scales, and Care Outcomes in ALS, SMA, and Other Motor System Disorders
This observational registry collects existing medical and routine care data from people with amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and other motor system disorders.
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), SMA - Spinal Muscular Atrophy, Spinal Cord Diseases, Central Nervous System Diseases
- Trial name
- NCT07900672
- Testing
- Standard of Care (Investigator Choice)
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- Ambulanzpartner Soziotechnologie APST GmbH
Amyotrophic Lateral Sclerosis (ALS)
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
The primary objective of this study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip once a day in patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24…
- Trial name
- NCT00330681
- Testing
- MCI-186
- Volunteers
- 206 people
- Sponsor
- Shionogi
Colon Cancer
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
The goal of this clinical trial is to learn if giving two medicines together, porustobart and pembrolizumab, before surgery can treat a common type of colon cancer called microsatellite stable (MSS) colon cancer in adults.
- Trial name
- NCT07808151
- Testing
- Pembrolizumab, Porustobart
- Where
- 30 sites in United States, Belgium and 4 more
- Volunteers
- 100 people
- Sponsor
- Solstice Oncology, Inc.
Neuropathic Pain, Spinal Cord Injuries
Clinical Trial to Evaluate Safety, Tolerability and Efficacy of NFX88 in SCI
In summary, this small-scale study is designed to demonstrate that the NFX88 is safe and well tolerated, as well as preliminary evidence of improvement in the score of VAS, PD-Q, and PGIC scales.
- Trial name
- NCT04148573
- Testing
- NFX88 - 1, NFX88 - 2, NFX88 - 3
- Where
- 7 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Neurofix S.L.
Amyotrophic Lateral Sclerosis (ALS)
The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects with Amyotrophic Lateral Sclerosis
- Trial name
- NCT07118319
- Testing
- Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)
- Where
- China
- Volunteers
- 12 people
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Neuralgia, Spinal Cord Injuries
A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
The purpose of this study is to evaluate if pregabalin relieves nerve pain associated with spinal cord injury compared to placebo (pill that contains no active medicine).
- Trial name
- NCT00407745
- Testing
- pregabalin
- Where
- 67 sites in United States, Chile and 8 more
- Volunteers
- 220 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Radiculopathy, Myelopathy
Post-Approval Clinical Trial of the PCM® Cervical Disc
On October 26, 2012, the FDA granted Premarket Approval (PMA) for the PCM Cervical Disc. PCM Cervical Disc is indicated for use in skeletally mature patients for reconstruction of a degenerated cervical disc at one level from…
- Trial name
- NCT01905930
- Testing
- PCM Cervical Disc, Anterior Cervical Discectomy and Fusion (ACDF)
- Where
- 18 sites in United States
- Volunteers
- 494 people
- Sponsor
- NuVasive
Amyotrophic Lateral Sclerosis
Early Feasibility Study of the MyoRegulator® for Treatment of ALS
This is a single-center, single-arm, open-label study aiming to assess the safety and feasibility of the MyoRegulator® device when used to treat individuals with amyotrophic lateral sclerosis (ALS).
- Trial name
- ALSEFS (NCT06165172)
- Testing
- MyoRegulator®
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- PathMaker Neurosystems Inc.
Neuropathic Pain
To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.
To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain after spinal cord injury.
- Trial name
- NCT00141375
- Testing
- Pregabalin
- Where
- 7 sites in Australia
- Volunteers
- 132 people
- Sponsor
- Pfizer
Poliomyelitis
Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®)
The trial is a phase 4, open-label, multicentre clinical trial with healthy subjects who have been vaccinated with IPV-Al AJV at 2, 4, 6 and 15 18 months of age in previous trials.
- Trial name
- NCT04448132
- Testing
- IPV-Al
- Where
- Panama
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- AJ Vaccines A/S
Diphtheria, Tetanus
Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE
PRIMARY OBJECTIVES To describe in 11 to 13-year-old children previously vaccinated with either REVAXIS or DT Polio at 6 years of age the antibody persistence against diphtheria, tetanus, and poliovirus types 1, 2 and 3 To…
- Conditions
- Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT01546909
- Testing
- Diphtheria, tetanus, polio and pertussis vaccination
- Where
- 45 sites in France
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Spinal Cord Injury
To Study the Safety and Efficacy of Autologous Bone Marrow Stem Cells in Patients With Spinal Cord Injury
This is a Phase I/II, multicenter, prospective, non-randomized, open label study to evaluate the safety/efficacy of autologous bone marrow-derived stem cell transplantation in spinal cord injury patients.
- Trial name
- ABSCI (NCT01730183)
- Testing
- Bone marrow derived stem cells
- Where
- India
- Volunteers
- 15 people
- Sponsor
- Max Institute of Neurosciences
Neurogenic Urinary Bladder, Neurogenic Bladder Disorder
Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions
This study will assess the safety, tolerability and efficacy of SAF312 in patients with overactive bladder disease due to spinal cord lesions.
- Conditions
- Neurogenic Urinary Bladder, Neurogenic Bladder Disorder, Neurogenic Dysfunction of the Urinary Bladder, Neurogenic Bladder, Uninhibited
- Trial name
- NCT01598103
- Testing
- SAF312
- Where
- 3 sites in Germany, Netherlands and 1 more
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Diphtheria, Polio
Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants
This is a follow-up of Study A3L10 (NCT00315055) Immunogenicity To describe the antibody persistence following a primary series vaccination of either DTaP-IPV-HB-PRP~T or PENTAXIM™ and ENGERIX B®.
- Conditions
- Diphtheria, Polio, Pertussis, Hepatitis B
- Trial name
- NCT00619502
- Testing
- DTaP-IPV-HB-PRP~T vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Spinal Cord Injury
A Phase I Safety Study of NVG-291 in Healthy Adults
This is a randomized, triple-blind (subjects, Investigators, and Sponsor blinded), placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) study to evaluate the safety and tolerability of NVG-291…
- Trial name
- NCT05308953
- Testing
- NVG-291
- Where
- Australia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- NervGen Pharma